PDCD1 and neoplasm: Interventions included PD-1 monoclonal antibodies (nivolumab and pembrolizumab), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody ibritumomab, and DC vaccines, all demonstrating good anti-tumor effects (Table 7).